Reviewing the Role of JAK Inhibitors in Atopic Dermatitis

Guest: Shawn Kwatra, MD

As the most common type of eczema, atopic dermatitis is a chronic, inflammatory skin disorder that affects millions of people worldwide. And although it’s a complex disease with no cure, the FDA recently approved two oral JAK-1 inhibitors for patients with mild-to-severe-symptoms. So what do we need to know about these new treatment options? Joining Dr. Matthew Keller to review the role of JAK inhibitors in atopic dermatitis is Dr. Shawn Kwatra, Associate Professor of Dermatology at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Itch Center.